ARK THERAPEUTICS LTD.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 5250
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 148
 
  
 
C07D HETEROCYCLIC COMPOUNDS 1161
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 198
 
  
 
C07K PEPTIDES 1135

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2014/0121,160 Use of VEGF in the Treatment of Retarded Fetal Growth in PregnancyOct 29, 12May 01, 14[A61K, A61P]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
8604070 Use of inhibitors of the renin-angiotensin systemJan 30, 12Dec 10, 13[A61K]
8334271 Use of VEGF in the treatment of retarded fetal growth in pregnancyFeb 22, 08Dec 18, 12[A61K, C07H, C12N]
8227606 Arginine derivatives with NP-1 antagonistic activityJan 30, 12Jul 24, 12[C07D]
8188039 VEGF-D mutants and their useJun 02, 08May 29, 12[A61K, C12N, C07K]
7998953 Use of inhibitors of the renin-angiotensin systemApr 29, 05Aug 16, 11[A61K]

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2012/0269,864 Arginine Derivatives with NP-I Antagonistic ActivityAbandonedJun 11, 12Oct 25, 12[A61K, C07F, C07D, C07C, A61P]
2012/0253,013 Early Growth Transcription Factors and Their Therapeutic UseAbandonedAug 25, 10Oct 04, 12[C12N, C07K]
2012/0201,749 NP-1 Antagonists and Their Therapeutic UseAbandonedAug 25, 10Aug 09, 12[A61K, C07D, A61P]
8158789 Arginine derivatives with NP-I antagonistic activityExpiredOct 04, 07Apr 17, 12[C07D]
2011/0052,540 Non-Aggregating Virus FormulationAbandonedAug 11, 08Mar 03, 11[A61K, C12Q, A61P]
2010/0221,791 Method for Incorporating Proteins Into Lentivirus VectorsAbandonedFeb 11, 08Sep 02, 10[C12N]
2009/0024,208 StentAbandonedJul 24, 06Jan 22, 09[A61F]
2009/0011,509 INTEGRASE FUSION PROTEINS AND THEIR USE WITH INTEGRATING GENE THERAPYAbandonedJan 14, 05Jan 08, 09[C12N]
2008/0280,363 Pseudotyped Baculovirus and its UseAbandonedNov 03, 05Nov 13, 08[C12N]
2008/0280,783 Baculovirus-Based Gene LibrariesAbandonedNov 03, 05Nov 13, 08[C07H, C40B]
7393677 Avidin-pseudotyped viral vectors and their useExpiredJul 06, 06Jul 01, 08[C12N]
2007/0224,675 Expression CassetteAbandonedMay 20, 05Sep 27, 07[C12N]
2007/0196,352 Vegf-induced genes and their therapeutic useAbandonedSep 16, 04Aug 23, 07[A61K]
7223835 VEGF peptides and their use for inhibiting angiogenesisExpiredOct 25, 01May 29, 07[A61K]
7208291 Nucleic acids encoding biotin-binding receptorsExpiredJul 11, 03Apr 24, 07[C12N]
2006/0166,868 Vegf peptides and their useAbandonedMar 28, 03Jul 27, 06[A61K, C07K]
7071183 Use of inhibitors of the renin-angiotensin systemExpiredJul 26, 02Jul 04, 06[A61K]
7022693 Treatment of lipodystrophyExpiredAug 07, 02Apr 04, 06[A61K]
2005/0201,983 Engineered baculoviruses and their useAbandonedSep 09, 04Sep 15, 05[A61K, C12N]
2005/0192,326 Use of inhibitors of the renin-angiotensin systemAbandonedApr 29, 05Sep 01, 05[A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.